Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Aptevo Therapeutics Inc

APVO ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$2.94

▼ -13.78%

Market Cap $4.46M · Vol 7.77K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$4.46M

Micro Cap

Div Yield

N/A

EPS Growth

+73.24%

YoY

RSI (14)

19.91

Momentum

Beta

1.61

vs Market

52W High

$48.60

93.95% below

52W Low

$2.84

3.52% above

Volume

7.77K

Avg 11.66K

P/B

0.54

Price-to-book

ROE

N/A

Return on equity

Free Float

93.07%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Aptevo Therapeutics Inc (APVO) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does APVO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-29.67%

-36.36%

-38.69%

-56.18%

YTD

-68.82%

-91.99%

-100.00%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-25,967,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-121.38% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.54
P/FCF	N/A
EPS Growth	+73.24%
Outstanding Shares	1.52M

Technical Indicators

50-Day SMA	$4.38
200-Day SMA	$9.19
RSI (14)	19.91
Beta	1.61
52-Week High	$48.60
52-Week Low	$2.84

Volume Today	7.77K
Avg Daily Volume (30D)	11.66K
Relative Volume	0.67x
Volatility (10D)	97.24
Volatility (30D)	84.86
Free Float	93.07%

Analyst Consensus

BUY

Current Price $2.94

Mean Target $21.00

52W Low$2.84 52W High$48.60

Current

Target

$2.84 $48.60

Current Analyst target

+614.29% upside potential · 2 analysts

Identifiers

ExchangeNasdaq

FIGIBBG009RRZ8D1

ISINUS03835L7029

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateAug 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.